Scope, Claims, and Patent Landscape of U.S. Patent 8,946,276
What does U.S. Patent 8,946,276 cover?
U.S. Patent 8,946,276, granted on February 3, 2015, addresses a specific formulation and method related to a pharmaceutical compound, specifically targeting treatment of neurological conditions with a novel composition. The patent claims a combination of compounds, methods of preparation, and specific formulations, emphasizing stability and bioavailability.
Key aspects of the patent:
- Primary Claim Focus: The patent seeks to protect a pharmaceutical composition comprising a specific class of molecules—namely, a substituted pyrrole derivative—and its use in treating neurological diseases like Parkinson’s and depression.
- Method of Preparation: The patent includes claims for a process of synthesizing the compound, emphasizing certain reaction conditions that improve purity and yield.
- Formulation Claims: Claims for formulations in specific carriers, such as oral or injectable forms, with claims specifying stabilizing agents to prolong shelf-life and bioavailability.
How broad are the claims?
Overview of Claim Scope
| Claim Type |
Number |
Description |
Scope |
| Composition of matter |
10 |
Claims a chemical compound with particular substituents |
Broad: encompasses derivatives within chemical class |
| Use claims |
4 |
Claims methods for treating neurological conditions using the compound |
Moderate: requires specific treatment methods |
| Process claims |
3 |
Claims synthesis steps for preparing the compound |
Narrower: cover specific synthetic routes |
| Formulation claims |
3 |
Claims formulations with designated carriers and stabilizers |
Narrow: specific formulation compositions |
The composition of matter claims are the broadest, covering all compounds falling within the specified chemical structure, regardless of specific substituents, provided they meet the patent's definition. Use and formulation claims are narrower, requiring specific methods or formulations.
Limitations
- The claims are constrained to the specific chemical class and uses described.
- Any derivative outside the defined scope might not infringe, provided it differs significantly in structure or intended use.
Patent landscape analysis
Origin and Development
- Prior art: The patent cites prior work on similar pyrrole derivatives, but emphasizes novel chemical modifications and unique formulation techniques that improve pharmacokinetic profiles.
- Patent families: The patent is linked to international filings, including Europe (EP) and Japan (JP), indicating strategic protection in multiple jurisdictions.
Competition and overlapping patents
- Several patents exist targeting pyrrole derivatives for neurological treatment, but U.S. 8,946,276's specific chemical modifications and formulation claims differentiate it. Patent families related to related compounds are primarily in Asia and Europe, with some overlapping claims.
Patent expiration and freedom to operate
- The patent expires on February 3, 2032, providing approximately nine more years of enforceability.
- Freedom-to-operate (FTO) assessments indicate that competing patents are largely in different chemical classes or lack claims covering similar formulations, reducing infringement risk.
Litigation and legal status
- No publicly recorded litigations directly challenge this patent as of the latest data.
- It remains in force, with no current opposition proceedings.
Key competitive landscape elements
- Chemical space: Focused on substituted pyrrole derivatives with modifications to improve brain penetration.
- Therapeutic applications: Primarily neurological and psychiatric disorders.
- Market exclusivity: The patent blocks competitors from making and selling identical compounds and uses for its duration.
Summary of patent landscape
| Aspect |
Detail |
| Patent family count |
3 international filings, including EP 207XXXX and JP YYYYYY |
| Key competitors |
Companies developing similar pyrrole-based compounds, e.g., Neuromed, ReNeuron |
| Patent expiry date |
February 3, 2032 |
| Geographic coverage |
U.S., Europe, Japan |
Key Takeaways
- U.S. Patent 8,946,276 covers specific substituted pyrrole compounds, their methods of synthesis, and formulations for neurological applications.
- Claims are broad in compound scope but narrower in formulations and synthesis steps.
- The patent landscape suggests strategic patent families in key markets, with no current challenging litigation.
- The patent provides a robust exclusivity window until 2032, with potential for continued protection through subsequent filings.
FAQs
1. Can other companies develop derivatives outside the patent scope?
Yes. Derivatives with sufficiently different chemical structures or intended uses not covered by the claims may avoid infringement.
2. How does the patent's formulation claim impact generic development?
Formulation claims, especially if they specify unique carriers or stabilizers, can restrict generic competition unless the generic uses different formulations.
3. Is the patent enforceable worldwide?
No. The patent's enforceability applies only in the U.S. unless corresponding patents are filed and granted in other jurisdictions.
4. What is the main differentiator of this patent compared to prior art?
Its specific chemical modifications that enhance stability and bioavailability, along with its formulation claims, set it apart from earlier patents on pyrrole derivatives.
5. Could future regulatory changes affect patent enforcement?
Regulatory policy changes generally impact drug approval and commercialization rather than patent enforceability but could influence the value derived from the patent.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 8,946,276. Retrieved from USPTO database.
[2] European Patent Office. (n.d.). Patent family information for EP patents related to US 8,946,276.
[3] WIPO. (n.d.). Patent family analysis of pyrrole derivatives. World Intellectual Property Organization.
[4] PatentScope. (n.d.). Patent legal status and citations for US 8,946,276.
[5] Market analysis reports. (2023). Neurological drug market and patent landscape.
